CodeBreak 100 is a single-group, phase I/II trial aiming to assess the safety and efficacy of sotorasib treatment in pretreated patients with KRAS G12C–mutated pancreatic cancer. Results from the study were recently published by Strickler et al in The New England Journal of Medicine.
